Mapi is the leading Patient-Centered Research company serving academia, life science researchers, and the pharmaceutical industry for over 40 years. Mapi’s commitment to patient-focused research is demonstrated not only by our expertise and nearly four decades of service but also through our direct contribution back to the industry. Mapi is among only a handful of global organizations that is capable of engaging with a patients’ complete ecosystem, their HCPs, Patient Communities, payers, and even regulators. And only Mapi has the unique history to make us the most experienced at interacting with all of them.
|Headquarters||27 rue de la Villette Lyon, 69003 France|
|Number of employees||501-1000 employees|
2015 - Mapi acquires select Optum Life Science services, including: North American and European Regulatory Consulting, Late Phase CRO and European Health Economics and Outcomes REesearch (HEOR) teams
2014 - Mapi celebrates a strong history and looks forward to even greater accomplishments in the future.
2013 - James Karis comes aboard as chief executive officer
2012- Mapi values France, Netherlands and some members of Bostonteam become 100% Mapi
2009- Mapi acquires Registrat, one of the three leaders in post-marketing studies in the US ,welcoming their 140 employees to the global Mapi family
2007- Mapi acquires JNB Developpement, one of the leaders in Market access in France
2004- Mapi Research Trust is founded. Non-profit organization facilitating access to information in the field of Patient-Centered Outcomes and encouraging exchanges between between academics, pharmaceutical companies and international organizations around the world.
2001- Mapi acquires Naxis, a French company specializing in late phase studies
1999- At the initiative of the ERIQA group, launch of the PRO Harmonization Group which brings together the member of ERIQA,ISOQOL,ISPOR and the "Health Outcomes Committee" of PhRMA and the FDA (Laurie Burke) in order to harmonize the guidelines on the use of PRO tools in clinical studies. This resulted in the creation of the PRO Guidance document finalized by the FDA in 2009
1997- Mapi establishes the ERIQA group to develop some guidelines on the use of HRQL evaluation in drug development
1995-1997 Mapi Values grows in Boston and the Netherlands
1994-1995 Donald Patrick spends a sabbatical year in Lyon France working on developing Mapi's QOL expertise and cross-cultural adaptation of health outcomes instruments.
1993- Mapi Values UK is founded. Joint venture with Adelphi Group to develop our QOL expertise worldwide.
1991- First QOL newsletter is launched with the collaboration with Catherine Acquadro,as well as IQOLA projectin close collabortion with John Ware's team.
1990- John Ware, Dick Joyce, Pennifer Erickson and Neil Aaronson participate in the first symposium on QOL organized by Mapi for the pharma industry
1989- First QOL study for Ciba Geigy is initiated for TTS Estraderm; Dick Joyce intrtoduces team to QOL
1988- John Ware enters the picture,facilitating the decision to develop our expertise of patient QOL evaluation
1987- Roche Labs choose Mapi for their large Phase IV for Ticotil requested by health authorities
1985- Mapi wins the bid of the French Pharmaceutical Companies Association (LEEM) for the development of French hospital's panel
1981- Jean-Louis Menard joins Mapi to develop the medical market research activity
1974-1980Market research activity develops with its first clients in pharma industry, Becton Dickinson and Pfizer
September 1974 Mapi SARL Market Research founded by Bernard Jambon, first study in Brazilfor the BOIRON labs and AMORA
- Real World Evidence
- Patient Centered Sciences
- Real World Stratedgy and Analytics
- Language Services
- Strategic Regulatory Services
- Mapi Research Trust
Top 5 Recent News Headlines
Press Release: Mapi Creates Dedicated Patient Centered Sciences Unit by Combining Patient Centered Outcomes, Patient Insights and Engagement and Direct To Patient Contact Services